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ail address: patricia.fernandez.sspa@juntadea b s t r a c tObjectives: To evaluate the Bio-Rad D-100s, an HPLC analyzer for glycated hemoglobin
(HbA1c) determination, and to compare its performance with the Menarini HA-8180Vs
and Sysmex G8s.
Methods: Method comparison was performed according to Clinical and Laboratory Stan-
dards Institute (CLSI) EP9-A2 guidelines. We selected 100 samples from the routine la-
boratory workload and analyzed them in duplicate with the three analyzers. The im-
precision study was performed according to CLSI EP5-A2 guidelines for both inter-assay
and intra-assay variability. Bias was assessed with external quality control material. To
establish linearity, CLSI EP6-A protocol was followed.
Results: Method comparison (95% confidence intervals in parentheses): D-100 vs G8:
Passing-Bablok regression; y¼0.973(0.963–0.983) 0.07(0.070.069); r¼0.9989.
Bland-Altman mean difference: 0.229%HbA1c (0.256: 0.202); Relative bias plot: D-
100/G8 vs D100-G8 mean ratio¼0.971(0.9670.975). D-100 vs HA-8180V: Passing-Ba-
blok regression; y¼0.944(0.932–0.958) 0.078(0.0240.173); r¼0.9989. Bland-Alt-
man mean difference: 0.363%HbA1c (0.401: 0.325); Relative bias plot D-100/HA-
8180V vs D100-HA-8180V mean ratio¼0.955(0.9520.958). Inter-assay coefficient of
variation (CV): 0.81%. Intra-assay CV: 1.04% (low level), and 0.78% (high level). Bias against
target value¼2.332%. Linearity: r2¼0.998 in the concentration range 4.413.9%HbA1c.
Carry-over: 0.0024%.
Conclusions: The Bio-Rad D-100 shows good correlation with G8 and HA-8180V. There is a
small proportional systematic difference (2.7% and 5.6%, respectively) in both compar-
isons. Inter and intra-assay CVs are both lower than the lowest CV obtained in studies
performed with D-100 and other instruments.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes Mellitus (DM) has become a global epidemic whose incidence is increasing and which already affects one in
twelve people [1] and reduces the quality of life for many millions of people through its complications (retinopathy, renal,
vascular and heart diseases, etc.). As a result, glycated hemoglobin (HbA1c) is a fundamental parameter in the clinical
laboratory, as it has been determined to be an effective, stable and comfortable alternative to blood glucose for bother B.V. This is an open access article under the CC BY-NC-ND license
.
andalucia.es (P. Fernández-Riejos).
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HbA1c is an ideal parameter for diagnosis and control of DM because there is a direct relationship between average blood
glucose levels and HbA1c concentration [4]. HbA1c is a derivative of hemoglobin, a minor fraction that is generated as a result
of non-enzymatic reaction between the aldehyde group of the open structure of the glucose molecule and the free amino
group in the terminal valine of the hemoglobin β chain. This reaction occurs with the formation of an unstable intermediate,
a Schiff base known as labile hemoglobin. Then, after an Amadori rearrangement, it is stabilized in its ketoamine form
constituting HbA1c [5].
HbA1c can be determined by different techniques [6], which are based on chemical and structural differences between
HbA1c and other hemoglobin fractions. One of those techniques is ion exchange High Performance Liquid Chromatography
(HPLC), which exploits the fact that the ionization point (pI) of HbA1c is different from other hemoglobin fractions. It uses a
cation exchange resin to separate HbA1c.
Although HbA1c determination for diagnosing and monitoring DM has some limitations, such as the presence of some
possible interferences (hemoglobinopathies, carbamylated and labile hemoglobin) or altered half-life of red blood cells
(renal failure, hemolytic anemia, etc.), the advantages are many [7]. In addition, many of the disadvantages have been
overcome in the newly developed analyzers and for many of them the most common hemoglobin variants do not pose a
problem, nor do the carbamylated hemoglobin [8] or labile hemoglobin [6].
HPLC techniques are considered the gold standard in the determination of HbA1c and are among the most widespread in
clinical laboratories. In this study we compared the performance of three HPLC analyzers for HbA1c.2. Materials and methods
We studied three HbA1c analyzers: G8s from Tosoh Bioscience (Tokyo, Japan) (G8); D-100s from Bio-Rad Laboratories
(Hercules, CA, USA) (D-100); and HA-8180Vs from A Menarini Diagnostics (Firenze, Italy) (HA-8180V). These three in-
struments employ the same measurement principle: ion exchange HPLC, preceded by a pre-filter to avoid the rapid dete-
rioration of the column. The detection system is a photometer, which quantifies the different hemoglobin fractions iden-
tified by their specific retention time.
The instruments were calibrated according to the manufacturers’ specifications and we performed daily internal quality
control with two levels of quality control, one high and one low, provided by the manufacturers.3. Assessment protocol
3.1. Method comparison
Method comparison was performed according to Clinical and Laboratory Standards Institute (CLSI; Wayne, PA, USA) EP9-
A2 guidelines. From venous blood samples (collected into EDTA tubes) received for the determination of HbA1c in the
routine laboratory, we selected 100 samples and divided them into 4 concentration ranges (25 samples per range): 4–6%
HbA1c (20.22–42.08 mmol/mol Hb), 6–8% HbA1c (42.08–63.93 mmol/mol Hb), 8–10% HbA1c (63.9385.79 mmol/mol Hb)
and 410% HbA1c (485.79 mmol/mol Hb), overall concentration range of the samples used: 4.6–12.15% HbA1c (26.78–
109.29 mmol/mol Hb). We analyzed the samples in duplicate on all three analyzers with less than 2 h between the first and
last samples.
3.2. Precision
The precision study was performed according to CLSI EP5-A2 guidelines for both inter-assay and intra-assay variability.
The inter-assay variability was determined with a pool of samples, aliquoted and frozen at 80 °C. We measured one
aliquot per day for twenty consecutive days.
For intra-assay variability we selected two samples: one with a high HbA1c value and other with a low HbA1c value. We
measured both samples twenty consecutive times in the same run.
3.3. Accuracy
The bias of the method was assessed by analyzing for twenty consecutive days the three levels of Liquichecks Diabetes
Control from Bio-Rad (Hercules, CA), prepared from whole human blood for external quality control. Using the results
obtained from the D-100 and the target value we calculated total and relative bias.
3.4. Linearity
To establish the linearity, CLSI EP6-A protocol was followed. We selected two samples with values 4.4% and 13.9% HbA1c,
respectively (both samples had the same hemoglobin concentration, 13.7 g/dL). The samples were mixed according to the
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3.5. Carry-over
Carry-over was assessed following the “Protocols for Determination of Limits of Detection and Limits of Quantitation”
(1986) [9]. We used 2 samples: High sample (H) with 14% HbA1c, and Low sample (L) with 5% HbA1c. We analyzed them in
the following order: L1L2L3H1H2L4H3H4L5L6L7L8H5H6L9H7H8L10H9H10L11 [9].
3.6. Statistical analysis
For the method comparison we used Passing-Bablok non parametric regression and Pearson correlation coefficient
(r) was calculated. The confidence intervals (95%) were determined. The bias was estimated using a Bland-Altman plot and a
relative difference plot. Coefficients of variation (CV%) were calculated to estimate the intra and inter-assay variability. Data
analysis and statistical calculations were performed using Method Validator (Philippe Marquis Software) and SPSS (IBM
Analytics, Armonk, NY, USA).4. Results
4.1. Method comparison D-100 vs G8
Passing-Bablok non parametric regression analysis showed a slope of 0.973 with a 95% confidence interval (CI) of (0.963–
0.983), and an intercept of 0.07, with CI (0.07: 0.069) (Fig. 1). The Pearson Correlation Coefficient between both
measurement methods was 0.9989.
The Bland-Altman plot (Fig. 2) shows a mean difference of 0.229%HbA1c (CI: 0.256: 0.202).
Relative bias plot (Fig. 3) D-100/G8 vs D100-G8 gives a mean ratio (D-100/G8) of 0.971 (CI: 0.9670.975).
 D-100 vs HA-8180V
Passing-Bablok regression (Fig. 4) showed a slope of 0.944 (CI: 0.932–0.958), and intercept of 0.078 (CI: 0.0240.173);
r¼0.9989 (Fig. 3).Fig. 1. Passing-Bablok non-parametric regression; D-100 vs G8; y¼0.973(0.963–0.983) 0.07(0.070.069); r¼0.9989. (95% confidence intervals in
parentheses).
Fig. 2. Bland-Altman difference plot; D-100 vs G8; mean difference (D-100G8)¼0.229% HbA1c (95% CI: 0.256: 0.202).
Fig. 3. Relative bias plot; D-100/G8 vs mean value of D100 and G8; mean ratio (D-100/G8)¼0.971 (95% CI: 0.9670.975).
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Relative bias plot (Fig. 6) D-100/HA-8180V vs mean of D100 and HA-8180V gives a mean ratio (D-100/HA-8180V) of
0.955(0.9520.958). Fig. 7.4.2. Imprecision and bias
Results for inter-assay and intra-assay variability are shown in Table 1 in both National Glycohemoglobin Standardization
Program (NGSP; % HbA1c) and International Federation of Clinical Chemistry (IFCC; mmol/mol Hb) units.4.3. Linearity and carry-over
The instrument response in the concentration range between 4.4% and 13.9% HbA1c (24.6–128.4 mmol/mol Hb) was
completely linear, (r2¼0.9935). The percentage of carry-over calculated for the instrument was 0.0024% in NGSP units
(%HbA1c) and 0.026% in IFCC units (mmol/mol Hb).
Fig. 4. Passing-Bablok non-parametric regression; D-100 vs HA-8180V; y¼0.944(0.932–0.958) 0.078 (0.0240.173); r¼0.9989. 95% confidence in-
tervals in parentheses.
Fig. 5. Bland-Altman difference plot; D-100 vs HA-8180V; mean difference (D-100HA-8180V)¼0.363 (95% CI: 0.401: 0.325).
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The Bio-Rad D-100 shows good correlation with both reference instruments Tosoh G8 and Menarini HA-8180V, with a
Pearson correlation coefficient of 0.998, the same for both comparisons. This value agrees with the one published in another
similar study, in which the D-100 is compared with another HPLC instrument [10].
On a more detailed analysis with a Passing-Bablok regression, it was observed that, both using G8 as reference instrument,
and in the comparison with HA-8180V, the intercepts for both regression lines did not show statistically significant differences
between the methods. The 95% confidence intervals (CI) both included zero. However, the slopes, with confidence intervals
(0.963–0.983) and (0.932–0.958), for G8 and HA-8180V respectively, slightly deviate from the ideal slope, showing a small
proportional systematic difference that can be quantified at 2.7% against the G8 and 5.6% against the HA-8180V.
This systematic difference appears again in the results in Bland-Altman plots (Figs. 2 and 5), which shows a negative bias
for high HbA1c values present in both comparisons, quantified in the mean differences obtained. In the comparison with G8
Fig. 6. Relative bias plot; D-100/HA-8180V vs mean value of D-100 and HA-8180V; mean ratio (D-100/HA-8180V)¼0.955 (95%CI: 0.9520.958).
Fig. 7. Linearity of the instrument in the range between 4.4% and 13.9% HbA1c (24.6–128.4 mmol/mol Hb). In the graph we plotted the values obtained in
D-100 for the 5 dilutions on the Y axis, versus the theoretical values calculated for the dilutions on the X axis.
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the differences with a relative bias plot (Figs. 3 and 6), there is still an important bias present, but it affects the whole range
of HbA1c concentrations, reaching in the case of D100/G8 plot a similar value to the proportional error obtained for the
Passing-Bablok: 2.9% (mean ratio¼0.971) but higher in D-100/HA-8180V plot: 4.5% (mean ratio¼0.955).
This problem with bias also appears in the accuracy study. The evaluation of bias using an external quality control
(Table 1) proved again the existence of a negative bias in D-100. And, as the results in Bland-Altman plot expressed, the bias
is greater for higher HbA1c concentrations (1.55% for Liquicheck 1 at 5.34%HbA1c, 1.931% for Liquicheck 2 at 9.5% HbA1c, and
3.515% for Liquicheck 3 at 14.6%HbA1c). This progressive bias might be due to a problem with the calibration protocol or
traceability of calibration materials. Nevertheless, it seems to affect mainly higher HbA1c concentrations, in which case it
would not be a critical interference in clinical or diagnostic decisions.
HbA1c is a longitudinal parameter, used in monitoring diabetes over the patient's lifetime. Therefore, the reproducibility
and repeatability of HbA1c measurements must be well controlled. To assess the variability in the D-100 instrument, we
determined intra-assay CV with two samples, one with a low concentration of HbA1c (4.7%) and one with a high con-
centration (11.4%), obtaining CV values of 1.05% (%HbA1c) [1.97% (mmol/mol)] and 0.78% (%HbA1c) [0.99% (mmol/mol)],
respectively. Both CVs are lower than the lowest CV obtained in several studies performed with the D-100 [10] and with
other instruments [11]. Also, these CV values meet the recommendations made by Sacks et al. [12] of within-laboratory CV
below 2%. The inter-assay CV% estimated was 0.81% (%HbA1c) [1.51% (mmol/mol)], an excellent result which meets the
criteria required for the determination of HbA1c [13], which are higher in IFCC units (mmol/mol) than in NGSP units (%
HbA1c) [14].
The linear response of the instrument has been confirmed in the range between 3.4% and 13.9%HbA1c (24.6–128.4 mmol/
mol), which represents the HbA1c concentration range involved in diagnostic decisions.
Table 1.
Results of the imprecision and bias study in both %HbA1c and mmol/mol Hb units. The inter-assay variability was calculated measuring the same pool for
twenty consecutive days. For intra-assay variability two samples: one high and one low HbA1c concentration were processed twenty consecutive times. To
estimate bias we used the target values for three levels of an external quality control material (Liquichek Diabetes Controls; Bio-Rad).
Precision (%HbA1c) Mean SD CV (%)
Inter-assay variability 6.06 0.049 0.81
Intra-assay variability 11.39 0.089 0.78
4.75 0.050 1.05
Bias (%HbA1c) Level 1 Level 2 Level 3 Average
(5.34) (9.5) (14.6)
Total 0.082 0.18 0.496 0.252
% 1.55 1.931 3.515 2.332
Precision (mmol/mol Hb) Mean SD CV (%)
Inter-assay variability 42.46 0.641 1.51
Intra-assay variability 100.98 0.997 0.99
28.36 0.558 1.97
Bias (mmol/mol Hb) Level 1 Level 2 Level 3 Average
(34.8) (80.4) (136)
Total 0.827 2.039 5.352 2.739
% 2.435 2.602 4.097 3.045
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analyte. Carryover for the D-100 was tested using the method described by Peters [10]. The result is a carry-over quantified
as 0.0024% (%HbA1c)/0.026% (mmol/mol Hb), which is very satisfactory and similar to carry-over calculated for other ana-
lyzers [15] ensuring that there is no contamination after measuring concentrated samples.
Finally, D-100 provides a number of advantages in daily operation, such as the incorporation of computer and control
software on the instrument itself, controlled through an easy-to-use touch screen. Through the screen the operator has
access to all system controls and configurations; maintenance procedures, change of reagents, performance of analyses, data
collection and inspection of chromatograms. The change of reagents, column and pre-filter is very simple and can be done
with the equipment running, it not being necessary to change the column for up to 10,000 determinations. Also an excellent
throughput should be noted allowing the achievement of only 45 s per determination, which is better than the throughput
of the G8 and HA-8180V.References
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